QCMD to use RNAssist’s virusPHIX-P9™ Biomolecule Stabilization Technology in its SARS-CoV-2 antigen EQA scheme In a further development of the collaboration between QCMD and RNAssist, QCMD will use the universal biological sample stabilization virusPHIX-P9™ as the matrix within its forthcoming SARS-CoV-2 antigen EQA pilot scheme. Image Credit: Rapid Labs Studies have proven that virusPHIX-P9™ is both capable of inactivating SARS-CoV-2 as well as stabilizing clinical samples at ambient temperatures. Extensive testing at QCMD has shown that virusPHIX-P9™ is compatible with a variety of SARS-CoV-2 antigenic tests including a wide range of Lateral Flow tests (LFT). Related Stories The QCMD SARS-CoV-2 Antigen EQA Pilot Scheme will consist of both positive and negative whole inactivated SARS-CoV-2 in virusPHIX-P9™ and will allow the performance assessment of applied clinical laboratory antigenic tests as well as rapid antigenic tests such as lateral flow assays used within public health practice. Further information can be obtained via the QCMD website.